KCM Investment Advisors LLC Sells 11,730 Shares of Johnson & Johnson (NYSE:JNJ)

KCM Investment Advisors LLC cut its position in shares of Johnson & Johnson (NYSE:JNJ) by 5.3% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 209,961 shares of the company’s stock after selling 11,730 shares during the period. Johnson & Johnson comprises 1.0% of KCM Investment Advisors LLC’s portfolio, making the stock its 28th biggest position. KCM Investment Advisors LLC’s holdings in Johnson & Johnson were worth $30,365,000 at the end of the most recent reporting period.

Several other hedge funds have also made changes to their positions in the company. Oregon Pacific Wealth Management LLC purchased a new stake in Johnson & Johnson during the fourth quarter worth $949,000. Horan Securities Inc. raised its position in shares of Johnson & Johnson by 1.3% in the 4th quarter. Horan Securities Inc. now owns 7,178 shares of the company’s stock worth $1,038,000 after acquiring an additional 90 shares in the last quarter. Strategic Financial Concepts LLC boosted its position in Johnson & Johnson by 57.9% during the fourth quarter. Strategic Financial Concepts LLC now owns 3,467 shares of the company’s stock valued at $501,000 after purchasing an additional 1,271 shares in the last quarter. Lord Abbett & CO. LLC purchased a new position in Johnson & Johnson in the third quarter valued at about $69,859,000. Finally, KPP Advisory Services LLC raised its holdings in Johnson & Johnson by 4.7% in the fourth quarter. KPP Advisory Services LLC now owns 11,492 shares of the company’s stock worth $1,662,000 after purchasing an additional 515 shares in the last quarter. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Johnson & Johnson Trading Down 4.3 %

Shares of Johnson & Johnson stock opened at $153.03 on Friday. The stock has a market cap of $368.77 billion, a PE ratio of 23.01, a price-to-earnings-growth ratio of 2.56 and a beta of 0.47. The firm has a fifty day moving average price of $159.75 and a 200 day moving average price of $155.91. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $169.99. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.11 and a quick ratio of 0.86.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, beating analysts’ consensus estimates of $1.99 by $0.05. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The business had revenue of $22.52 billion during the quarter, compared to analyst estimates of $22.44 billion. During the same quarter last year, the business posted $2.29 EPS. The company’s revenue was up 5.3% on a year-over-year basis. Equities research analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current year.

Insiders Place Their Bets

In related news, VP Robert J. Decker sold 6,999 shares of the stock in a transaction on Tuesday, February 25th. The shares were sold at an average price of $165.88, for a total transaction of $1,160,994.12. Following the sale, the vice president now directly owns 21,001 shares of the company’s stock, valued at approximately $3,483,645.88. This represents a 25.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, EVP Timothy Schmid sold 403 shares of Johnson & Johnson stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total transaction of $62,928.45. Following the completion of the transaction, the executive vice president now directly owns 15,098 shares of the company’s stock, valued at $2,357,552.70. The trade was a 2.60 % decrease in their position. The disclosure for this sale can be found here. Insiders own 0.16% of the company’s stock.

Analyst Ratings Changes

A number of research firms have recently weighed in on JNJ. Bank of America raised their price target on shares of Johnson & Johnson from $159.00 to $171.00 and gave the company a “neutral” rating in a report on Wednesday, March 5th. Guggenheim reaffirmed a “neutral” rating on shares of Johnson & Johnson in a report on Wednesday. Royal Bank of Canada reiterated an “outperform” rating and set a $181.00 price objective on shares of Johnson & Johnson in a report on Wednesday. Raymond James dropped their target price on Johnson & Johnson from $170.00 to $165.00 and set an “outperform” rating on the stock in a research note on Thursday, January 23rd. Finally, Stifel Nicolaus decreased their price target on Johnson & Johnson from $170.00 to $155.00 and set a “hold” rating for the company in a research note on Thursday, January 23rd. Nine research analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $171.33.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.